Delivery Order SPE2DB24D2003-SPE2DB24FXFQ2

Award Date 7/17/24
Potential Completion Date 7/18/24
Potential Value $5.6K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $1,789.02, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Valsartan-HCTZ 160-12.5 mg tablets in 90-count packages. This award is not designated under any set-aside program. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA, valued at $999,999,999 and...
This is a $3,615.46 delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Valsartan-HCTZ 160-12.5 mg tablets in 90-count packages. The contract has an ultimate completion date of March 12, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $8,440.96, is for the delivery of Valsartan-HCTZ 160-12.5 mg tablets in 90-count packages. The contract has a firm fixed price and an ultimate completion date of July 11, 2024. This appears to be a delivery order under a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $17,252.52, is for the delivery of valsartan-HCTZ 320-25 mg tablets. The award is a delivery order under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical division. This IDC serves as a primary vehicle for providing a...
This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $31,985.62, is for the delivery of Valsartan-HCTZ 80-12.5 mg tablets. The contract is a Firm Fixed Price Delivery Order, with an ultimate completion date of January 7, 2025. It is not associated with any set-aside designation, indicating open competition. Amerisourcebergen holds a significant...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $27,198.16, is a Firm Fixed Price Delivery Order for the supply of Valsartan-HCTZ 160-12.5 mg tablets in 90-count bottles. The contract is not designated as a set-aside and appears to be part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support...
This is a federal contract award issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of valsartan-HCTZ 320-25 mg tablets in 90-count packages, with a total ceiling value of $1,742.24 and a period of performance through December 9, 2024. The contract is a delivery order under an existing Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen...
This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,621.15 delivery order contract is for Valsartan-HCTZ 160-12.5 mg tablets, a cardiovascular medication, with a period of performance through July 2024. This award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop Support Medical, which provides a...
This federal contract award, valued at $8,434.46, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Valsartan-Hctz 160-12.5 mg tablets in quantities of 90 per bottle. This is a firm fixed-price delivery order contract with a completion date of May 24, 2024. The contract is not designated as a set-aside. Amerisourcebergen holds a significant Indefinite...
This is a federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) for the delivery of valsartan-HCTZ 160-12.5 mg tablets. The contract has a ceiling value of $3,258.46 and runs through March 19, 2025. This appears to be a delivery order issued under a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued at $999,999,999 and expiring in November 2026. The contract...
  • SPE2DB24D2003
    Indefinite Delivery Contract
  • SPE2DB24D2003-SPE2DB24FXFQ2
    Delivery Order

This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $5,614.28, is for the delivery of Valsartan-HCTZ 160-12.5 mg tablets in 90-count bottles. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract award does not have a set-aside designation, indicating open competition.

Generated 5/17/25, 10:08 AM